Bone CancerOpen to EnrollmentPhase 1

ADVANCED SOLID TUMORS: Phase 1: PD-L1 + novel agent: GO43860

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

View on ClinicalTrials.gov Browse more trials

Study snapshot

Title: Genentech GO43860 Phase I broad
Malignancy: Esophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage: Stage 4
Disease setting: Metastatic/Palliative
Line of therapy: >1st line
Investigational agent: RO7502175
Drug class: Anti-CCR8 antibody
Principal investigator: Dan Vaena, MD
Sponsor: Genentech, Inc.
Intervention arm: RO7502175 +/- Atezolizumab
Path: Carcinoma
Randomized: No
ClinicalTrials.gov ID: NCT05581004

Eligibility and objectives

Key eligibility criteria details

Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumors
Must have tumor specimen available
Measurable disease
ECOG PS 0-1
Life expectancy at least 12 weeks
Phase 1a- must have exhausted all standard therapies for their disease
Phase 1b- must have disease that has progressed after at least one available standard therapy
Some cohorts are tumor-type specific- please contact study team to see if tumor type is eligible at any time during the study
No active HBV/HCV or chronic or acute EBV
No history of autoimmune disease
No symptomatic or actively progressing CNS mets

Objective

Primary
- DLT
- TEAE
Secondary
- PK
- ORR
- DoR
- PFS
- Anti-drug antibody

Study snapshot

Eligibility and objectives

Key eligibility criteria details

Objective

Treatment details